Bioject has posted a net loss of $580,000 for the second quarter 2010, or $0.03 loss per diluted share, compared to $313,000, or $0.02 per diluted share, for the comparable period in 2009. Operating loss was $593,000, compared to $108,000 for the comparable period in 2009.
For the six months ended June 30, 2010, Bioject has posted a revenue of $2.35m compared to $3.66m for the year ago period. Operating loss was $1.1m, compared to $283,000m for the year ago period.
For the six months ended June 30, 2010, Bioject has posted a net loss of $1.15m, or $0.06 per diluted share, compared to $550,000m, or $0.03 per diluted share, for the year ago period.
Ralph Makar, president and CEO of Bioject, said: “The challenges of lower revenue for the second quarter and increased spending on future opportunities influenced our operating results for the quarter ended June 30, 2010, over the same period last year.
“During the second quarter of 2010, we significantly increased investment on pursuing new business opportunities. Even with these efforts, our cash position at the end of the second quarter of 2010 was comparable to our cash position at the end of the first quarter of 2010.
“We believe that the investments made and the active plan we have been working on will yield improved results during the latter half of the year. As we focus on future opportunities, we are also pursuing potential sources of additional capital either through the closure of new contracts or from other sources.”
